Last reviewed · How we verify
Ketorolac and nefopam balanced analgesia
Ketorolac and nefopam balanced analgesia is a Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved.
At a glance
| Generic name | Ketorolac and nefopam balanced analgesia |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac and nefopam balanced analgesia CI brief — competitive landscape report
- Ketorolac and nefopam balanced analgesia updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about Ketorolac and nefopam balanced analgesia
What is Ketorolac and nefopam balanced analgesia?
Ketorolac and nefopam balanced analgesia is a Small molecule drug developed by Seoul National University Hospital.
Who makes Ketorolac and nefopam balanced analgesia?
Ketorolac and nefopam balanced analgesia is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).
What development phase is Ketorolac and nefopam balanced analgesia in?
Ketorolac and nefopam balanced analgesia is FDA-approved (marketed).